<div id="readability-page-1"><p>Evan Seigerman, an analyst from BMO Capital, maintained the Hold rating on Replimune Group. The associated price target remains the same with $11.00.</p><div><p>Evan Seigerman has given his Hold rating due to a combination of factors, primarily the binary nature of the upcoming April 10 PDUFA outcome for RP1. While the recent departure of a key FDA figure and acceptance of the resubmitted BLA modestly enhance perceived approval odds, he sees ongoing political and media pressures on the agency as limiting conviction on any single regulatory scenario.</p><p>  At the same time, he recognizes that RP1 appears to be a meaningful therapy in an area of significant unmet need and could anchor a viable skin cancer franchise if approved. However, despite Replimune’s current cash providing a runway through the decision and early launch activities, a further CRL would leave the company with an uncertain path and likely inadequate funding for new pivotal work, justifying a neutral, wait‑and‑see stance. </p></div><p>In another report released yesterday, TipRanks – PerPlexity also upgraded the stock to a Hold with a $7.00 price target.</p></div>

LABU

SBIO

REPL

IBBQ

<p>Evan Seigerman from BMO Capital has maintained a Hold rating on Replimune Group with a price target of $11.00, citing the binary nature of the upcoming PDUFA outcome for RP1 as a key factor. Despite some improvements in approval odds, ongoing political pressures limit confidence in regulatory outcomes. While RP1 could address significant unmet needs in skin cancer, uncertainty remains regarding funding for future pivotal work, justifying a neutral stance. TipRanks also upgraded the stock to a Hold with a $7.00 price target.</p>

Tip Ranks

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Replimune

SPDR S&P Biotech

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Replimune: Binary RP1 PDUFA Outcome and Funding Overhang Justify Hold Rating